Pfizer (NYSE:PFE) Stock Rating Cut to “Hold” at DZ Bank

Posted by Brenda Bartman on Nov 7th, 2026

DZ Bank cut shares of Pfizer (NYSE:PFE – Free Report) from a buy rating to a hold rating in a research note released on Friday, Marketbeat.com reports.

Other equities analysts have also issued research reports about the company. Citigroup upped their price target on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday. Royal Bank Of Canada lifted their price objective on Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. UBS Group upped their target price on shares of Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, HSBC upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Six analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.39.

View Our Latest Report on Pfizer

Pfizer Price Performance

Shares of NYSE PFE traded down $0.50 during mid-day trading on Friday, hitting $29.38. 48,291,518 shares of the stock were exchanged, compared to its average volume of 30,697,644. The company has a market cap of $167.46 billion, a P/E ratio of 41.97, a PEG ratio of 2.08 and a beta of 0.31. The stock’s fifty day simple moving average is $28.74 and its two-hundred day simple moving average is $26.90. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.44.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the company earned $0.87 EPS. Pfizer’s revenue for the quarter was down .4% on a year-over-year basis. As a group, analysts forecast that Pfizer will post 3.03 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is presently 245.71%.

Institutional Trading of Pfizer

Hedge funds have recently modified their holdings of the company. Retirement Wealth Solutions LLC lifted its holdings in Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 509 shares in the last quarter. Keb Asset Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $26,000. Field & Main Bank bought a new stake in Pfizer during the 2nd quarter worth approximately $27,000. Bullseye Investment Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $28,000. Finally, Timbuktu Capital Management LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $29,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips